As medical director, Dr. Nash will provide clinical and administrative leadership and serve as a liaison between the clinical staff and hospital operational leadership for the Cancer Center. He will also serve as the medical liaison to the community.
Dr. Nash earned his medical degree from the University of Texas Health Science Center in San Antonio, Texas, and completed both his internship and residency at Cleveland Metropolitan General Hospital in Cleveland, Ohio. He completed his fellowship at the University of Arizona School of Medicine in Tuscon, Ariz.
“We are honored to have Dr. Nash as our new medical director,” says Anthony Williamson, vice president of Greater Braselton and Service Line Development. “An experienced oncologist and previous medical director, Dr. Nash brings over 30 years of expertise and knowledge to our cancer program. Dr. Nash’s experience is a bit different, in that in addition to his clinical experience, he has held administrative leadership positions in the past as well, thus making him somewhat uniquely qualified for this role. He also has an inclusive style to leadership, which will help us continue to build relationships throughout our region.”
Dr. Nash has been a member of the NGMC medical staff and practiced at The Longstreet Clinic, P.C. since 1999. Prior to moving to Gainesville, he served as CEO and medical director of the Harrington Cancer Center in Amarillo, Texas. He also previously practiced at the LaFortune Cancer Center and Eastern Oklahoma Hematology-Oncology in Tulsa, Okla.
Dr. Nash and his wife, Mary Theresa, live in Gainesville.
The Cancer Center at NGMC is accredited by the American College of Surgeons’ Commission on Cancer.
The Cancer Center provides state-of-the-art radiation therapy, chemotherapy and biologic and hormone therapies, as well as innovative techniques such as prostate seed implant therapy, sentinel node biopsy, stereotactic radiation therapy and robotic surgery treatments. The Cancer Center also offers approximately 70 ongoing cancer clinical trials, ensuring that patients have access to the latest research advances in cancer treatment.